 | Up a level |
Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Gorlov, J. S., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Levis, A., Krause, S., Schmoll, H. J., Hertenstein, B., Zaccaria, A., Guarini, A., Atta, J., Bassan, R., Cervetti, J., Elter, T., Enggaard, L., Haenel, M., Kneba, M., Liberati, M., Martelli, M., Martens, U., Morra, E., Pinto, A., Zaja, F., Ponzoni, M., Deckert, M., Politi, L. S., Finke, J., Reni, M., Cavalli, F., Zucca, E. and Illerhaus, G. (2017). Autologous stem cell transplantation (ASCT) or whole-brain radiotherapy (WBRT) as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary cns lymphoma (PCNSL): results of the IELSG32 randomized Phase II Trial. Bone Marrow Transplant., 52. S. S96 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Illerhaus, G., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L. S., Fox, C. P., La Rose, P., Ambrosetti, A., Roeth, A., Hemmaway, A., Ilariucci, F., Linton, K. M., Soffietti, R., Pukrop, T., Binder, M., Balzarotti, M., Fabbri, A., Johnson, P., Gorlov, J. S., Cavalli, F., Finke, J., Schorb, E., Reni, M., Zucca, E. and Ferrer, A. J. M. (2015). Improved outcome with addition of thiotepa and rituximab to methotrexate and cytarabine in primary cns lymphoma: Results of the first randomization of the IELSG-32 trial. Oncol. Res. Treat., 38. S. 177 - 178. BASEL: KARGER. ISSN 2296-5262
Tempero, M., Oh, D-Y, Tabernero, J., Reni, M., Van Cutsem, E., Hendifar, A., Waldschmidt, D-T, Starling, N., Bachet, J-B, Chang, H-M, Maurel, J., Garcia-Carbonero, R., Lonardi, S., Coussens, L. M., Fong, L., Tsao, L. C., Cole, G., Jr., James, D. and Macarulla, T. (2021). Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann. Oncol., 32 (5). S. 600 - 609. AMSTERDAM: ELSEVIER. ISSN 1569-8041